Li Zheng-An, Wen Kai-Chao, Liu Ji-Heng, Zhang Chuan, Zhang Feng, Li Feng-Qian
School of Medicine, Shanghai University, Shanghai 200444, China.
Department of Urology/Pharmaceutics, Shanghai Eighth People's Hospital, Shanghai 200235, China.
Acta Pharm Sin B. 2024 Nov;14(11):4738-4755. doi: 10.1016/j.apsb.2024.07.003. Epub 2024 Jul 6.
Intravesical drug delivery (IDD), as a noninvasive, local pathway of administration, has great clinical significance for bladder diseases, especially bladder cancer. Despite the many advantages of IDD such as enhanced focal drug exposure and avoidance of systemic adverse drug reactions, the effectiveness of drug delivery is greatly challenged by the physiological barriers of the bladder. In this review, the routes and barriers encountered in IDD are first discussed, and attention is paid to the potential internal/mucosal retention and absorption-transport mechanisms of drugs. On this basis, the avoidance, overcoming and utilization of the "three barriers" is further emphasized, and current design and fabrication strategies for intravesical drug delivery systems (IDDSs) are described mainly from the perspectives of constructing drug reservoirs, enhancing permeability and targeting, with the hope of providing systematic understanding and inspirations for the research of novel IDDSs and their treatment of bladder diseases.
膀胱内给药(IDD)作为一种非侵入性的局部给药途径,对膀胱疾病尤其是膀胱癌具有重要的临床意义。尽管IDD具有诸多优点,如增强局部药物暴露和避免全身性药物不良反应,但药物递送的有效性受到膀胱生理屏障的极大挑战。在本综述中,首先讨论了IDD中遇到的途径和屏障,并关注药物潜在的内部/黏膜滞留及吸收转运机制。在此基础上,进一步强调了对“三大屏障”的规避、克服和利用,并主要从构建药物储库、增强通透性和靶向性的角度描述了当前膀胱内给药系统(IDDSs)的设计和制备策略,以期为新型IDDSs的研究及其对膀胱疾病的治疗提供系统的认识和启发。